A Case of Therapy-related Acute Myeloid Leukemia associated with inv(16).
10.3343/kjlm.2007.27.1.19
- Author:
So Young LEE
1
;
Myungshin KIM
;
Jihyang LIM
;
Yonggoo KIM
;
Kyungja HAN
;
Sung Yong KIM
;
Hee Je KIM
;
In Yang PARK
Author Information
1. Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. yonggoo@catholic.ac.kr
- Publication Type:Case Report ; English Abstract
- Keywords:
Therapy-related AML;
Inv(16);
Alkylating agents;
Antimitotic agent
- MeSH:
Antimitotic Agents/*adverse effects/therapeutic use;
Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use;
Chromosomes, Human, Pair 16/*genetics;
Cisplatin/adverse effects/therapeutic use;
Female;
Humans;
*Inversion, Chromosome;
Leukemia, Myeloid, Acute/*chemically induced/pathology;
Middle Aged;
Taxoids/adverse effects/therapeutic use
- From:The Korean Journal of Laboratory Medicine
2007;27(1):19-21
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The inv(16)(p13q22) is found in de novo AML and is closely associated with the FAB subtype M4eo. The inv(16) is rarely reported in therapy-related AML (t-AML) patients. Herein, we report a case of t-AML with inv(16) after combination chemotherapy using antimitotic agent and alkylating agent (cis-platin-paclitaxel) for ovarian serous cystadenocarcinoma.
